Practical guidelines for the prevention and management of diabetic foot disease in China

Abstract

Diabetic foot (DF) is a prevalent and significant complication of diabetes mellitus. The primary factors that contribute to amputation and mortality in DF patients are multifaceted and include foot deformities, ulcers, ischemia, and potential concurrent infections. To further standardize DF prevention and treatment in China, improve consistency in DF diagnosis and treatment, and promote the development of a specialized tiered care system, the Chinese Burn Association, the Yangtze River Delta Integrated Diabetic Foot Alliance, and the Editorial Committee of the Chinese Journal of Burns and Wound Repair established a multidisciplinary expert team. The team identified clinical issues concerning the diagnosis, treatment, and prevention of DF via the population, interventions, comparisons, outcomes framework, assessed the quality of relevant evidence using the Grading of Recommendations Assessment, Development and Evaluation system, and ultimately formulated a consensus titled “Practical Guidelines for the Prevention and Management of Diabetic Foot Disease in China.” The guidelines include 46 recommendations that address comprehensive medical assessment; internal medical treatments, including treatments related to blood glucose, blood pressure, and blood lipid control; antithrombotic and anti-infection therapy; perioperative risk assessment and management; surgical interventions, such as debridement, vascular reconstruction, and tissue repair; foot disease prevention; multidisciplinary collaboration; and the establishment of a hierarchical diagnosis and treatment system, with the objective of guiding clinical practice for managing DF in China.

Keywords

Diabetic foot / Infection / Peripheral arterial disease / Peripheral neuropathy / Wound healing

References

[1] McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. Diabetes Care. 2023; 46: 209-21. https://doi.org/10.2337/dci22-0043.

[2] Bus SA, van Netten JJ, Lavery LA, Monteiro-Soares M, Rasmussen A, Jubiz Y, et al. IWGDF guidance on the prevention of foot ulcers in at-risk patients with diabetes. Diabetes Metab Res Rev. 2016; 32 Suppl 1: 16-24. https://doi.org/10.1002/dmrr.2696.

[3] Jiang Y, Wang X, Xia L, Fu X, Xu Z, Ran X, et al. A cohort study of diabetic patients and diabetic foot ulceration patients in China. Wound Repair Regen. 2015; 23: 222-30. https://doi.org/10.1111/wrr.12263.

[4] Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis (dagger). Ann Med. 2017; 49: 106-16. https://doi.org/10.1080/07853890.2016.1231932.

[5] Bao X, Yang C, Fang K, Shi M, Yu G, Hu Y. Hospitalization costs and complications in hospitalized patients with type 2 diabetes mellitus in Beijing, China. J Diabetes. 2017; 9: 405-11. https://doi.org/10.1111/1753-0407.12428.

[6] Lu Q, Wang J, Wei X, Wang G, Xu Y, Lu Z, et al. Cost of diabetic foot ulcer Management in China: a 7-year single-Center retrospective review. Diabetes Metab Syndr Obes. 2020; 13: 4249-60. https://doi.org/10.2147/DMSO.S275814.

[7] Zhang Y, Liu H, Yang Y, Feng C, Cui L. Incidence and risk factors for amputation in Chinese patients with diabetic foot ulcers: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024; 15: 1405301. https://doi.org/10.3389/fendo.2024.1405301.

[8] Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017; 376: 2367-75. https://doi.org/10.1056/NEJMra1615439.

[9] Wang A, Lv G, Cheng X, Ma X, Wang W, Gui J, et al. Guidelines on multidisciplinary approaches for the prevention and management of diabetic foot disease (2020 edition). Burns Trauma. 2020; 8: tkaa017. https://doi.org/10.1093/burnst/tkaa017.

[10] Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64: 383-94. https://doi.org/10.1016/j.jclinepi.2010.04.026.

[11] Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182: E839-42. https://doi.org/10.1503/cmaj.090449.

[12] Chen Y, Yang K, Marusic A, Qaseem A, Meerpohl JJ, Flottorp S, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med. 2017; 166: 128-32. https://doi.org/10.7326/M16-1565.

[13] Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358: j4008. https://doi.org/10.1136/bmj.j4008.

[14] Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928. https://doi.org/10.1136/bmj.d5928.

[15] Stang A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603-5. https://doi.org/10.1007/s10654-010-9491-z.

[16] Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155: 529-36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009.

[17] Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic foot ulcers: a review. JAMA. 2023; 330: 62-75. https://doi.org/10.1001/jama.2023.10578.

[18] Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Fitridge R, Game F, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev. 2024; 40: e3657. https://doi.org/10.1002/dmrr.3657.

[19] Senneville E, Albalawi Z, van Asten SA, Abbas ZG, Allison G, Aragon-Sanchez J, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Diabetes Metab Res Rev. 2024; 40: e3687. https://doi.org/10.1002/dmrr.3687.

[20] Senneville E, Albalawi Z, van Asten SA, Abbas ZG, Allison G, Aragon-Sanchez J, et al. Diagnosis of infection in the foot of patients with diabetes: a systematic review. Diabetes Metab Res Rev. 2024; 40: e3723. https://doi.org/10.1002/dmrr.3723.

[21] Van Asten SA, Nichols A, La Fontaine J, Bhavan K, Peters EJ, Lavery LA. The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis. Int Wound J. 2017; 14: 40-5. https://doi.org/10.1111/iwj.12545.

[22] Huang Y, Cao Y, Zou M, Luo X, Jiang Y, Xue Y, et al. A comparison of tissue versus swab culturing of infected diabetic foot wounds. Int J Endocrinol. 2016; 2016: 8198714. https://doi.org/10.1155/2016/8198714.

[23] Nelson A, Wright-Hughes A, Backhouse MR, Lipsky BA, Nixon J, Bhogal MS, et al. CODIFI (concordance in diabetic foot ulcer infection): a cross-sectional study of wound swab versus tissue sampling in infected diabetic foot ulcers in England. BMJ Open. 2018; 8: e019437. https://doi.org/10.1136/bmjopen-2017-019437.

[24] Tardaguila-Garcia A, Garcia-Alvarez Y, Sanz-Corbalan I, Lopez-Moral M, Molines-Barroso RJ, Lazaro-Martinez JL. Could X-ray predict Long-term complications in patients with diabetic foot osteomyelitis? Adv Skin Wound Care. 2022; 35: 1-5. https://doi.org/10.1097/01.ASW.0000834460.20632.18.

[25] Calvo-Wright MDM, Alvaro-Afonso FJ, Lopez-Moral M, Garcia-Alvarez Y, Garcia-Morales E, Lazaro-Martinez JL. Is the combination of plain X-ray and probe-to-bone test useful for diagnosing diabetic foot osteomyelitis? A systematic review and meta-analysis. J Clin Med. 2023; 12. https://doi.org/10.3390/jcm12165369.

[26] Xu J, Cheng F, Li Y, Zhang J, Feng S, Wang P. Erythrocyte sedimentation rate combined with the probe-to-bone test for fast and early diagnosis of diabetic foot osteomyelitis. Int J Low Extrem Wounds 2021; 20: 227-31. https://doi.org/10.1177/153473462092327.

[27] Moallemi SK, Niroomand M, Tadayon N, Forouzanfar MM, Fatemi A. Diagnostic value of erythrocyte sedimentation rate and C reactive protein in detecting diabetic foot osteomyelitis; a cross-sectional study. Arch Acad Emerg Med 2020; 8: e71.

[28] Chen X, Shen Y, Wang Y, Li Y, Guo S, Liang Y, et al. Decreased accuracy of erythrocyte sedimentation rate in diagnosing osteomyelitis in diabetic foot infection patients with severe renal impairment: a retrospective cross-sectional study. PLoS One 2022; 17: e0265769. https://doi.org/10.1371/journal.pone.0265769.

[29] Gramberg M, Knippers C, Lagrand RS, van Hattem JM, de Goffau MC, Budding AE, et al. Concordance between culture, molecular culture and Illumina 16S rRNA gene amplicon sequencing of bone and ulcer bed biopsies in people with diabetic foot osteomyelitis. BMC Infect Dis 2023; 23: 505. https://doi.org/10.1186/s12879-023-08472-w.

[30] Schechter MC, Ali MK, Risk BB, Singer AD, Santamarina G, Rogers HK, et al. Percutaneous bone biopsy for diabetic foot osteomyelitis: a systematic review and meta-analysis. Open Forum Infect Dis 2020; 7: ofaa393. https://doi.org/10.1093/ofid/ofaa393.

[31] Leone A, Bianco NC, D’Ambra G, Lucchesi S, La Rosa E, Infante A, et al. The role of serial radiographs in diagnosing diabetic foot bone osteomyelitis. Mediterr J Hematol Infect Dis 2022; 14: e2022055. https://doi.org/10.4084/MJHID.2022.055.

[32] Jin Y, Huang K, Shao T. [(18)F]Fluorodeoxyglucose ([(18)F]FDG) positron emission tomography and conventional imaging modalities in the diagnosis of diabetic foot osteomyelitis: a meta-analysis. Clin Radiol 2024; 79: e1142-51. https://doi.org/10.1016/j.crad.2024.05.015.

[33] Feron F, de Ponfilly GP, Potier L, Gauthier DC, Salle L, Laloi-Michelin M, et al. Reliability and safety of bedside blind bone biopsy performed by a Diabetologist for the diagnosis and treatment of diabetic foot osteomyelitis. Diabetes Care 2021; 44: 2480-6. https://doi.org/10.2337/dc20-3170.

[34] Wudhikulprapan W, Phinyo P, Hadi A, Kanthawang T, Choudur HN. Diagnosing osteomyelitis in diabetic foot by diffusion-weighted imaging and dynamic contrast material-enhanced magnetic resonance imaging: a systematic review and meta-analysis. Clin Radiol 2024; 79: 805-17. https://doi.org/10.1016/j.crad.2024.07.015.

[35] Xu J, Chen W, He L, Feng S, Zhang J, Chang B. Most postoperative reserved “normal” metatarsal stumps of diabetic foot osteomyelitis are infected but have healing potential. Front Endocrinol (Lausanne). 2023; 14: 1165305. https://doi.org/10.3389/fendo.2023.1165305.

[36] Tarricone A, Mata K, Gee A, Axman W, Buricea C, Mandato MG, et al. A systematic review and meta-analysis of the effectiveness of LRINEC score for predicting upper and lower extremity necrotizing fasciitis. J Foot Ankle Surg. 2022; 61: 384-9. https://doi.org/10.1053/j.jfas.2021.09.015.

[37] Martucci JA, Riemer K. Gas-producing infections in the foot at a large Academic Medical Center: a 10-year retrospective review. J Foot Ankle Surg. 2023; 62: 360-4. https://doi.org/10.1053/j.jfas.2022.09.004.

[38] Ozer Balin S, Ozcan EC, Ugur K. A new inflammatory marker of clinical and diagnostic importance in diabetic foot infection: systemic immune-inflammation index. Int J Low Extrem Wounds. 2022;15347346221130817. https://doi.org/10.1177/15347346221130817.

[39] Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008; 31: 1679-85. https://doi.org/10.2337/dc08-9021.

[40] Lauri C, Leone A, Cavallini M, Signore A, Giurato L, Uccioli L. Diabetic foot infections: the diagnostic challenges. J Clin Med. 2020; 9. https://doi.org/10.3390/jcm9061779.

[41] Iacopi E, Sbarbaro C, Pieruzzi L, Lorenzi I, Baroni L, Goretti C, et al. Necrotizing fasciitis and diabetic foot: results of a prompt identification, surgery and antibiotic therapy (P.I.S.A.) protocol. Int J Low Extrem Wounds. 2023; 22: 733-41. https://doi.org/10.1177/15347346211041452.

[42] Toschi A, Giannella M, Viale P. Recurrence of skin and soft tissue infections: identifying risk factors and treatment strategies. Curr Opin Infect Dis. 2025; 38: 71-7. https://doi.org/10.1097/QCO.0000000000001096.

[43] Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015; 3: 105-13. https://doi.org/10.1016/S2213-8587(14)70219-0.

[44] Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the Management of Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024; 149: e1313-410. https://doi.org/10.1161/CIR.0000000000001251.

[45] Stoberock K, Kaschwich M, Nicolay SS, Mahmoud N, Heidemann F, Riess HC, et al. The interrelationship between diabetes mellitus and peripheral arterial disease. Vasa. 2021; 50: 323-30. https://doi.org/10.1024/0301-1526/a000925.

[46] Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt CA, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer. J Vasc Surg. 2023; 78: 1101-31. https://doi.org/10.1016/j.jvs.2023.07.020.

[47] Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024; 45: 3538-700. https://doi.org/10.1093/eurheartj/ehae179.

[48] Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019; 69: 3S-125S.e40. https://doi.org/10.1016/j.jvs.2019.02.016.

[49] Grozinger G, Pohmann R, Schick F, Grosse U, Syha R, Brechtel K, et al. Perfusion measurements of the calf in patients with peripheral arterial occlusive disease before and after percutaneous transluminal angioplasty using MR arterial spin labeling. J Magn Reson Imaging. 2014; 40: 980-7. https://doi.org/10.1002/jmri.24463.

[50] Mogilevskaya M, Gaviria-Carrillo M, Feliciano-Alfonso JE, Barragan AM, Calderon-Ospina CA, Nava-Mesa MO. Diagnostic accuracy of screening tests for diabetic peripheral neuropathy: an umbrella review. J Diabetes Res. 2024; 2024: 5902036. https://doi.org/10.1155/jdr/5902036

[51] Korst GS, Ratliff HT, Torian J, Jimoh RO, Jupiter DC. Delayed diagnosis of Charcot foot: a systematic review. J Foot Ankle Surg. 2022; 61: 1109-13. https://doi.org/10.1053/j.jfas.2022.01.008.

[52] Raspovic KM, Schaper NC, Gooday C, Bal A, Bem R, Chhabra A, et al. Diagnosis and treatment of active charcot neuroosteoarthropathy in persons with diabetes mellitus: a systematic review. Diabetes Metab Res Rev. 2024; 40: e3653. https://doi.org/10.1002/dmrr.3653.

[53] Wukich DK, Schaper NC, Gooday C, Bal A, Bem R, Chhabra A, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes Metab Res Rev. 2024; 40: e3646. https://doi.org/10.1002/dmrr.3646.

[54] Monteiro-Soares M, Hamilton EJ, Russell DA, Srisawasdi G, Boyko EJ, Mills JL, et al. Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024; 40: e3648. https://doi.org/10.1002/dmrr.3648.

[55] Monteiro-Soares M, Hamilton EJ, Russell DA, Srisawasdi G, Boyko EJ, Mills JL, et al. Classification of foot ulcers in people with diabetes: A systematic review[J]. Diabetes Metab Res Rev. 2024; 40:e3645. https://doi.org/10.1002/dmrr.3645

[56] Branch Group of Diabetic Foot and Peripheral Vascular Disease, Chinese Diabetes Society.Clinical pathway for the management of diabetic foot in China (2023 edition). Chin J Endocrinol Metab. 2023; 39: 93-102. https://doi.org/10.3760/cma.j.cn311282-20221014-00583.

[57] Korber A, Klode J, Al-Benna S, Wax C, Schadendorf D, Steinstraesser L, et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges. 2011; 9: 116-21. https://doi.org/10.1111/j.1610-0387.2010.07535.x.

[58] Korber A, Jockenhofer F, Sondermann W, Stoffels-Weindorf M, Dissemond J. First manifestation of leg ulcers: analysis of data from 1000 patients. Hautarzt. 2017; 68: 483-91. https://doi.org/10.1007/s00105-017-3950-3.

[59] Dissemond J, Placke JM, Moelleken M, Kroger K. The differential diagnosis of leg ulcers. Dtsch Arztebl Int. 2024; 121: 733-9. https://doi.org/10.3238/arztebl.m2024.0133.

[60] Probst S, Saini C, Gschwind G, Stefanelli A, Bobbink P, Pugliese MT, et al. Prevalence and incidence of venous leg ulcers-a systematic review and meta-analysis. Int Wound J. 2023; 20: 3906-21. https://doi.org/10.1111/iwj.14272.

[61] Nicoara M, Bain K, Patel R, Jaikaran O, Hingorani A, Asher E. Malignant transformation of nonhealing ulcer-basal cell carcinoma.Ann Vasc Surg. 2021; 70: 565.e7-10. https://doi.org/10.1016/j.avsg.2020.01.100.

[62] Barbe M, Batra A, Golding S, Hammond O, Higgins JC, O’Connor A, et al. Pyoderma gangrenosum: a literature review. Clin Podiatr Med Surg. 2021; 38: 577-88. https://doi.org/10.1016/j.cpm.2021.06.002.

[63] Ammad Ud Din M, Hussain SA, Jamshed S. Leg ulcer with long-term hydroxyurea use. Clin Case Reports. 2021; 9: 2487-8. https://doi.org/10.1002/ccr3.3991.

[64] Yan T, Dou Z, Claire M, Ellen K, Caroline M. Risk factors for first-ever diabetes-related foot ulcer: a systematic review and meta-analysis. Int Wound J. 2025; 22: e70728. https://doi.org/10.1111/iwj.70728.

[65] Shin JY, Roh SG, Sharaf B, Lee NH. Risk of major limb amputation in diabetic foot ulcer and accompanying disease: a meta-analysis. J Plast Reconstr Aesthet Surg. 2017; 70: 1681-8. https://doi.org/10.1016/j.bjps.2017.07.015.

[66] Xie Y, Zhang H, Ye T, Ge S, Zhuo R, Zhu H. The geriatric nutritional Risk index independently predicts mortality in diabetic foot ulcers patients undergoing amputations. J Diabetes Res. 2017; 2017: 5797194. https://doi.org/10.1155/2017/5797194.

[67] Lauwers P, Hendriks JMH, Van Bouwel S, Verrijken A, Van Dessel K, Van Gils C, et al. Malnutrition according to the 2018 GLIM criteria is highly prevalent in people with a diabetic foot ulcer but does not affect outcome. Clin Nutr ESPEN. 2021; 43: 335-41. https://doi.org/10.1016/j.clnesp.2021.03.029.

[68] Rodrigues BT, Vangaveti VN, Urkude R, Biros E, Malabu UH. Prevalence and risk factors of lower limb amputations in patients with diabetic foot ulcers: a systematic review and meta-analysis. Diabetes Metab Syndr. 2022; 16: 102397. https://doi.org/10.1016/j.dsx.2022.102397.

[69] Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, et al. Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2018; 28: 1081-91. https://doi.org/10.1016/j.numecd.2018.07.005.

[70] Liu C, Liang W, He X, Owusu-Agyeman M, Wu Z, Zhou Y, et al. Prognostic value of cysteine-rich protein 61 combined with N-terminal pro-B-type natriuretic peptide for mortality in acute heart failure patients with and without chronic kidney disease. Cardiorenal Med. 2020; 10: 11-21. https://doi.org/10.1159/000501929.

[71] Xu L, Qian H, Gu J, Shi J, Gu X, Tang Z. Heart failure in hospitalized patients with diabetic foot ulcers: clinical characteristics and their relationship with prognosis. J Diabetes. 2013; 5: 429-38. https://doi.org/10.1111/1753-0407.12062.

[72] Zaki HA, Bashir K, Iftikhar H, Alhatemi M, Elmoheen A. Evaluating the effectiveness of Pretreatment with intravenous fluid in reducing the Risk of developing contrast-induced nephropathy: a systematic review and meta-analysis. Cureus. 2022; 14: e24825. https://doi.org/10.7759/cureus.24825.

[73] Han XF, Zhang XX, Liu KM, Tan H, Zhang Q. Contrast-induced nephropathy in patients with diabetes mellitus between iso-and low-osmolar contrast media: a meta-analysis of full-text prospective, randomized controlled trials. PLoS One. 2018; 13: e0194330. https://doi.org/10.1371/journal.pone.0194330.

[74] Filimonov RV, Filimonova IV, Shapoval SD, Kobeliatskyi YY. Comparative analysis of the methods of anesthetic maintenance in patients with diabetes with the syndrome of diabetic foot requiring operative intervention. Wiad Lek. 2019; 72: 558-61. https://doi.org/10.36740/WLek201904110.

[75] Liu W, Zheng S, Du X. Association of Systemic Immune-Inflammation Index and Systemic Inflammation Response Index with diabetic kidney disease in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2024; 17: 517-31. https://doi.org/10.2147/DMSO.S447026.

[76] Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev. 2014; 6: CD007333. https://doi.org/10.1002/14651858.CD007333.pub2.

[77] Jia Y, Long D, Yang Y, Wang Q, Wu Q, Zhang Q. Diabetic peripheral neuropathy and glycemic variability assessed by continuous glucose monitoring: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2024; 213: 111757. https://doi.org/10.1016/j.diabres.2024.111757.

[78] Callaghan BC, Little AA, Feldman EL, Hughes RA, Cochrane Neuromuscular Group. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012; 2012: CD007543. https://doi.org/10.1002/14651858.CD007543.pub2.

[79] Lane KL, Abusamaan MS, Voss BF, Thurber EG, Al-Hajri N, Gopakumar S, et al. Glycemic control and diabetic foot ulcer outcomes: a systematic review and meta-analysis of observational studies. J Diabetes Complicat. 2020; 34: 107638. https://doi.org/10.1016/j.jdiacomp.2020.107638.

[80] Lan NSR, Dwivedi G, Fegan PG, Game F, Hamilton EJ. Unravelling the cardio-renal-metabolic-foot connection in people with diabetes-related foot ulceration: a narrative review. Cardiovasc Diabetol. 2024; 23: 437. https://doi.org/10.1186/s12933-024-02527-1.

[81] Werkman NCC, Driessen JHM, Klungel OH, Schaper NS, Souverein PC, Stehouwer CDA, et al. Incretin-based therapy and the risk of diabetic foot ulcers and related events. Diabetes Obes Metab. 2024; 26: 3764-80. https://doi.org/10.1111/dom.15721.

[82] Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program. Diabetologia. 2019; 62: 926-38. https://doi.org/10.1007/s00125-019-4839-8.

[83] Hodgson A, Gillies CL, Highton P, Haddon L, Gharibzadeh S, Zaccardi F, et al. Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: a systematic review and meta-analysis of observational cohort studies. Diabetes Obes Metab. 2024; 26: 2487-91. https://doi.org/10.1111/dom.15571.

[84] Du Y, Bai L, Fan B, Ding H, Ding H, Hou L, et al. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: a meta-analysis. Prim Care Diabetes. 2022; 16: 156-61. https://doi.org/10.1016/j.pcd.2021.12.007.

[85] Khan S, Mohammadnezhad M, Ratu A, Ghosh A, Ali W, Nand D, et al. Patterns and risk factors associated with index lower extremity amputations (LEA) among type 2 diabetes mellitus (T2DM) patients in Fiji. Prim Care Diabetes. 2021; 15: 1012-8. https://doi.org/10.1016/j.pcd.2021.07.007.

[86] Liu J, Yuan X, Liu J, Yuan G, Sun Y, Zhang D, et al. Risk factors for diabetic peripheral neuropathy, peripheral artery disease, and foot deformity among the population with diabetes in Beijing, China: a Multicenter, cross-sectional study. Front Endocrinol (Lausanne). 2022; 13: 824215. https://doi.org/10.3389/fendo.2022.824215.

[87] Hallstrom S, Svensson AM, Pivodic A, Olafsdottir AF, Londahl M, Wedel H, et al. Risk factors and incidence over time for lower extremity amputations in people with type 1 diabetes: an observational cohort study of 46,088 patients from the Swedish National Diabetes Registry. Diabetologia. 2021; 64: 2751-61. https://doi.org/10.1007/s00125-021-05550-z.

[88] Gomez-Marin B, Gomez-Delgado F, Lopez-Moreno J, Alcala-Diaz JF, Jimenez-Lucena R, Torres-Pena JD, et al. Long-term consumption of a Mediterranean diet improves postprandial lipemia in patients with type 2 diabetes: the Cordioprev randomized trial. Am J Clin Nutr. 2018; 108: 963-70. https://doi.org/10.1093/ajcn/nqy144.

[89] Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D’Emden MC, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009; 373: 1780-8. https://doi.org/10.1016/S0140-6736(09)60698-X.

[90] Teramoto T, Usami M, Takagi Y, Baccara-Dinet MT, Investigators OJ. Efficacy and safety of alirocumab in Japanese patients with diabetes mellitus: post-hoc subanalysis of ODYSSEY Japan. J Atheroscler Thromb. 2019; 26: 282-93. https://doi.org/10.5551/jat.45070.

[91] Chen Y, Yuan Z, Lu J, Eliaschewitz FG, Lorenzatti AJ, Monsalvo ML, et al. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: prespecified analysis of the Chinese population from the BERSON clinical trial. Diabetes Obes Metab. 2019; 21: 1464-73. https://doi.org/10.1111/dom.13700.

[92] Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial). Circulation. 2018; 137: 1571-82. https://doi.org/10.1161/CIRCULATIONAHA.117.030950.

[93] Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019; 139: e1082-143. https://doi.org/10.1161/CIR.0000000000000625.

[94] Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, et al. Baseline Low-density lipoprotein cholesterol and clinical outcomes of combining ezetimibe with statin therapy in IMPROVE-IT. J Am Coll Cardiol. 2021; 78: 1499-507. https://doi.org/10.1016/j.jacc.2021.08.011.

[95] Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2023 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014; 63: 2889-934. https://doi.org/10.1016/j.jacc.2013.11.002.

[96] Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019; 139: e1144-61. https://doi.org/10.1161/CIR.0000000000000626.

[97] Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019; 381: 1309-20. https://doi.org/10.1056/NEJMoa1908077.

[98] Bonaca MP, Bhatt DL, Simon T, Fox KM, Mehta S, Harrington RA, et al. Limb outcomes with ticagrelor plus aspirin in patients with diabetes mellitus and atherosclerosis. J Am Coll Cardiol. 2024; 83: 1627-36. https://doi.org/10.1016/j.jacc.2024.03.377.

[99] Roffi M, Landi A, Heg D, Frigoli E, Chalkou K, Chevalier B, et al. Abbreviated or standard antiplatelet therapy after PCI in diabetic patients at high bleeding Risk. JACC Cardiovasc Interv. 2024; 17: 2664-77. https://doi.org/10.1016/j.jcin.2024.08.030.

[100] Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial. Circulation. 2020; 141: 1841-54. https://doi.org/10.1161/CIRCULATIONAHA.120.046448.

[101] Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol. 2021; 6: 21-9. https://doi.org/10.1001/jamacardio.2020.4390.

[102] Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, et al. Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. J Am Coll Cardiol. 2018; 72: 3274-84. https://doi.org/10.1016/j.jacc.2018.09.078.

[103] Ajjan RA, Kietsiriroje N, Badimon L, Vilahur G, Gorog DA, Angiolillo DJ, et al. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J. 2021; 42: 2235-59. https://doi.org/10.1093/eurheartj/ehab128.

[104] Guo L, Pan Q, Cheng Z, Li Z, Jiang H, Zhang F, et al. Acetyllevocarnitine hydrochloride for the treatment of diabetic peripheral neuropathy: a phase 3 randomized clinical trial in China. Diabetes. 2024; 73: 797-805. https://doi.org/10.2337/db23-0377.

[105] Ran GL, Li YP, Lu LC, Lan SH. Disease-modifying therapies for diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Complicat. 2024; 38: 108691. https://doi.org/10.1016/j.jdiacomp.2024.108691.

[106] Wu CS, Huang YJ, Ko YC, Lee CH. Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials.Syst Rev. 2023; 12: 53. https://doi.org/10.1186/s13643-023-02185-6.

[107] Ponirakis G, Abdul-Ghani MA, Jayyousi A, Zirie MA, Qazi M, Almuhannadi H, et al. Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control. J Diabetes Investig. 2021; 12: 1642-50. https://doi.org/10.1111/jdi.13544.

[108] Fu Q, Yang H, Zhang L, Liu Y, Li X, Dai M, et al. Traditional Chinese medicine foot bath combined with acupoint massage for the treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis of 31 RCTs. Diabetes Metab Res Rev. 2020; 36: e3218. https://doi.org/10.1002/dmrr.3218.

[109] Alizadeh SD, Jahani S, Rukerd MRZ, Tabrizi R, Masoomi R, Banihashemian SZ, et al. Human studies of the efficacy and safety of stem cells in the treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis. Stem Cell Res Ther. 2024; 15: 442. https://doi.org/10.1186/s13287-024-04033-3.

[110] Anju M, Ummer Velladath S, Arun Maiya G, Hande M. A single blinded randomized controlled trial assessing the effect of photobiomodulation therapy on neuron specific biomarkers in type II diabetes mellitus patients with peripheral neuropathy. Diabetes Res Clin Pract. 2025; 222: 112087. https://doi.org/10.1016/j.diabres.2025.112087.

[111] Tatikola SP, Natarajan V, Desai VK, Asirvatham AR, Rajsekhar H. Effect of various exercise protocols on neuropathic pain in individuals with type 2 diabetes with peripheral neuropathy: a systematic review and meta-analysis. Diabetes Metab Syndr. 2022; 16: 102603. https://doi.org/10.1016/j.dsx.2022.102603.

[112] van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017; 39: 787-803.e18. https://doi.org/10.1016/j.clinthera.2017.02.010.

[113] Haanpaa M, Cruccu G, Nurmikko TJ, McBride WT, Docu Axelarad A, Bosilkov A, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 2016; 20: 316-28. https://doi.org/10.1002/ejp.731.

[114] Cruccu G, Nurmikko TJ, Ernault E, Riaz FK, McBride WT, Haanpaa M. Superiority of capsaicin 8% patch versus oral pregabalin on dynamic mechanical allodynia in patients with peripheral neuropathic pain. Eur J Pain. 2018; 22: 700-6. https://doi.org/10.1002/ejp.1155.

[115] Hussain N, Said ASA, Javaid FA, Al Haddad AHI, Anwar M, Khan Z, et al. The efficacy and safety profile of capsaicin 8% patch versus 5% lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients. J Diabetes Metab Disord. 2021; 20: 271-8. https://doi.org/10.1007/s40200-021-00741-2.

[116] Akahori H, Takamura T, Hayakawa T, Ando H, Yamashita H, Kobayashi K.Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Diabetes Res Clin Pract. 2004; 64: 153-9. https://doi.org/10.1016/j.diabres.2003.10.012.

[117] Eisenberg E, McNicol ED, Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain. 2006; 10: 667-76. https://doi.org/10.1016/j.ejpain.2005.10.007.

[118] Ardeleanu V, Toma A, Pafili K, Papanas N, Motofei I, Diaconu CC, et al. Current pharmacological treatment of painful diabetic neuropathy: a narrative review. Medicina (Kaunas). 2020; 56. https://doi.org/10.3390/medicina56010025.

[119] Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol. 2021; 78: 687-98. https://doi.org/10.1001/jamaneurol.2021.0538.

[120] Petersen EA, Stauss TG, Scowcroft JA, Jaasma MJ, Brooks ES, Edgar DR, et al. Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-month results of a randomized controlled trial. Diabetes Res Clin Pract. 2023; 203: 110865. https://doi.org/10.1016/j.diabres.2023.110865.

[121] Zhou PB, Sun HT, Bao M. Comparative analysis of the efficacy of spinal cord stimulation and traditional debridement Care in the Treatment of ischemic diabetic foot ulcers: a retrospective cohort study. Neurosurgery. 2024; 95: 313-21. https://doi.org/10.1227/neu.0000000000002866.

[122] Yao XC, Liu JP, Xu ZY, Wu Y, Pei FC, Zhang L, et al. Short-term spinal cord stimulation versus debridement for the treatment of diabetic foot: a retrospective cohort study. Asian J Surg. 2024. https://doi.org/10.1016/j.asjsur.2024.10.065.

[123] Chen JL, Hesseltine AW, Nashi SE, Sills SM, McJunkin TL, Patil S, et al. A real-world analysis of high-frequency 10 kHz spinal cord stimulation for the treatment of painful diabetic peripheral neuropathy. J Diabetes Sci Technol. 2022; 16: 282-8. https://doi.org/10.1177/19322968211060316.

[124] Wendland DM, Kline PW, Bohnert KL, Biven TM, Sinacore DR. Offloading of Diabetic Neuropathic Plantar Ulcers: Secondary Analysis of Step Activity and Ulcer Healing[J]. Adv Skin Wound Care. 2023; 36: 194-200. https://doi.org/10.1097/01.ASW.0000919476.24220.cc

[125] Vierhout BP, Visser R, Hutting KH, El Moumni M, van Baal JG, de Vries JPM. Comparing a non-removable total contact cast with a non-removable softcast in diabetic foot ulcers: A retrospective study of a prospective database[J]. Diabetes Res Clin Pract. 2022; 191: 110036. https://doi.org/10.1016/j.diabres.2022.110036

[126] Withers RV, Perrin BM, Landorf KB, Raspovic A. Offloading effects of a removable cast walker with and without modification for diabetes-related foot ulceration: a plantar pressure study[J]. J Foot Ankle Res. 2023; 16: 27. https://doi.org/10.1186/s13047-023-00625-z

[127] Berhane T, Jeyaraman K, Hamilton M, Falhammar H. Offloading Interventions for the Management of Charcot Neuroarthropathy in Diabetes[J]. Foot Ankle Orthop. 2025; 10: 24730114251315670. https://doi.org/10.1177/24730114251315670

[128] Gratwohl V, Jentzsch T, Schoni M, Kaiser D, Berli MC, Boni T, et al. Long-term follow-up of conservative treatment of Charcot feet[J]. Arch Orthop Trauma Surg. 2022; 142: 2553-66. https://doi.org/10.1007/s00402-021-03881-5

[129] Prem R, Vignaraja V, Lewis T, Budair B.Weight bearing versus non-weight bearing total contact cast in the management of active Charcot foot: a systematic review. SAGE Open Med. 2024; 12: 20503121241306957. https://doi.org/10.1177/20503121241306957.

[130] Macdonald KE, Boeckh S, Stacey HJ, Jones JD. The microbiology of diabetic foot infections: a meta-analysis. BMC Infect Dis. 2021; 21: 770. https://doi.org/10.1186/s12879-021-06516-7.

[131] Du F, Ma J, Gong H, Bista R, Zha P, Ren Y, et al. Microbial infection and antibiotic susceptibility of diabetic foot ulcer in China: literature review. Front Endocrinol (Lausanne). 2022; 13: 881659. https://doi.org/10.3389/fendo.2022.881659.

[132] Nieuwland AJ, Waibel FWA, Flury A, Lisy M, Berli MC, Lipsky BA, et al. Initial antibiotic therapy for postoperative moderate or severe diabetic foot infections: broad versus narrow spectrum, empirical versus targeted. Diabetes Obes Metab. 2023; 25: 3290-7. https://doi.org/10.1111/dom.15228.

[133] Rossel A, Lebowitz D, Gariani K, Abbas M, Kressmann B, Assal M, et al. Stopping antibiotics after surgical amputation in diabetic foot and ankle infections-a daily practice cohort. Endocrinol Diabetes Metab. 2019; 2:e00059. https://doi.org/10.1002/edm2.59.

[134] Pham TT, Gariani K, Richard JC, Kressmann B, Jornayvaz FR, Philippe J, et al. Moderate to severe soft tissue diabetic foot infections: a randomized, controlled, pilot trial of post-debridement antibiotic treatment for 10 versus 20 days. Ann Surg. 2022; 276: 233-8. https://doi.org/10.1097/SLA.0000000000005205.

[135] Cortes-Penfield NW, Armstrong DG, Brennan MB, Fayfman M, Ryder JH, Tan TW, et al. Evaluation and Management of Diabetes-related Foot Infections. Clin Infect Dis. 2023; 77: e1-13. https://doi.org/10.1093/cid/ciad255.

[136] Barwell ND, Devers MC, Kennon B, Hopkinson HE, McDougall C, Young MJ, et al. Diabetic foot infection: antibiotic therapy and good practice recommendations. Int J Clin Pract. 2017; 71. https://doi.org/10.1111/ijcp.13006.

[137] Kwon KT, Armstrong DG. Microbiology and antimicrobial therapy for diabetic foot infections. Infect Chemother. 2018; 50: 11-20. https://doi.org/10.3947/ic.2018.50.1.11.

[138] Li Y, Li L, Lin H, Li W, Wan J, Hao H, et al. Cold atmospheric plasma for promoting healing and anti-infection of chronic wounds: a meta-analysis. Clin Lab. 2025; 71. https://doi.org/10.7754/Clin.Lab.2024.241028.

[139] Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A, et al. A comprehensive review of Risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int J Mol Sci. 2023; 24. https://doi.org/10.3390/ijms24043169.

[140] Mangwani J, Houchen-Wolloff L, Malhotra K, Booth S, Smith A, Teece L, et al. UK foot and ankle thromboembolism (UK-FATE). Bone Joint J. 2024; 106-B: 1249-56. https://doi.org/10.1302/0301-620X.106B11.BJJ-2024-0128.R1.

[141] Bartlett MA, Mauck KF, Stephenson CR, Ganesh R, Daniels PR. Perioperative venous thromboembolism prophylaxis. Mayo Clin Proc. 2020; 95: 2775-98. https://doi.org/10.1016/j.mayocp.2020.06.015.

[142] Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382: 1994-2004. https://doi.org/10.1056/NEJMoa2000052.

[143] Bhardwaj B, Spertus JA, Kennedy KF, Jones WS, Safley D, Tsai TT, et al. Bleeding complications in lower-extremity peripheral vascular interventions: insights from the NCDR PVI registry. JACC Cardiovasc Interv. 2019; 12: 1140-9. https://doi.org/10.1016/j.jcin.2019.03.012.

[144] Haisley M, Sorensen JA, Sollie M. Postoperative pressure injuries in adults having surgery under general anaesthesia: systematic review of perioperative risk factors. Br J Surg. 2020; 107: 338-47. https://doi.org/10.1002/bjs.11448.

[145] Wei M, Wu L, Chen Y, Fu Q, Chen W, Yang D. Predictive validity of the Braden scale for pressure ulcer Risk in critical care: a meta-analysis. Nurs Crit Care. 2020; 25: 165-70. https://doi.org/10.1111/nicc.12500.

[146] Benson B, Benson A. Preoperative Anesthetic considerations in the podiatric surgical candidate.Clin Podiatr Med Surg. 2019; 36: 1-19. https://doi.org/10.1016/j.cpm.2018.08.001.

[147] Zou L, Wei Q, Pan S, Xiao F, Jiang Y, Zhong Y, et al. Comparison of the effects of combined femoral and sciatic nerves block versus general Anesthesia on hemodynamic stability and postoperative complication in patients with diabetic foot: a prospective, double-blind and randomized controlled trial. Diabetes Metab Syndr Obes. 2024; 17: 2243-57. https://doi.org/10.2147/DMSO.S465814.

[148] Knuf KM, Maani CV, Cummings AK. Clinical agreement in the American Society of Anesthesiologists physical status classification. Perioper Med (Lond). 2018; 7: 14. https://doi.org/10.1186/s13741-018-0094-7.

[149] Nube VL, White JM, Brewer K, Veldhoen D, Meler C, Frank G, et al. A randomized trial comparing weekly with every second week sharp debridement in people with diabetes-related foot ulcers shows similar healing outcomes: potential benefit to resource utilization. Diabetes Care. 2021; 44: e203-5. https://doi.org/10.2337/dc21-1454.

[150] Ahluwalia R, Vainieri E, Tam J, Sait S, Sinha A, Manu CA, et al. Surgical diabetic foot debridement: improving training and practice utilizing the traffic light principle. Int J Low Extrem Wounds. 2019; 18: 279-86. https://doi.org/10.1177/1534734619853657.

[151] Hajhosseini B, Chiou GJ, Dori G, Fukaya E, Chandra V, Meyer S, et al. Er:YAG laser vs. sharp debridement in management of chronic wounds: effects on pain and bacterial load. Wound Repair Regen. 2020; 28: 118-25. https://doi.org/10.1111/wrr.12764.

[152] Flores-Escobar S, Alvaro-Afonso FJ, Garcia-Alvarez Y, Lopez-Moral M, Lazaro-Martinez JL, Garcia-Morales E. Ultrasound-assisted wound (UAW) debridement in the treatment of diabetic foot ulcer: a systematic review and meta-analysis. J Clin Med. 2022; 11. https://doi.org/10.3390/jcm11071911.

[153] Chen P, Vilorio NC, Dhatariya K, Jeffcoate W, Lobmann R, McIntosh C, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024; 40: e3644. https://doi.org/10.1002/dmrr.3644.

[154] Ning P, Liu Y, Kang J, Cao H, Zhang J. Comparison of healing effectiveness of different debridement approaches for diabetic foot ulcers: a network meta-analysis of randomized controlled trials. Front Public Health. 2023; 11: 1271706. https://doi.org/10.3389/fpubh.2023.1271706.

[155] Vas P, Rayman G, Dhatariya K, Driver V, Hartemann A, Londahl M, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36 Suppl 1: e3284. https://doi.org/10.1002/dmrr.3284.

[156] Tan JS, Friedman NM, Hazelton-Miller C, Flanagan JP, File TM, Jr. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis. 1996; 23: 286-91. https://doi.org/10.1093/clinids/23.2.286.

[157] Faglia E, Clerici G, Caminiti M, Quarantiello A, Gino M, Morabito A. The role of early surgical debridement and revascularization in patients with diabetes and deep foot space abscess: retrospective review of 106 patients with diabetes. J Foot Ankle Surg. 2006; 45: 220-6. https://doi.org/10.1053/j.jfas.2006.04.002.

[158] Zhou S, Schmidt BM, Henig O, Kaye KS.Deferring amputation in diabetic foot osteomyelitis: doing more harm than good? Open Forum Infect Dis. 2021; 8: ofab184. https://doi.org/10.1093/ofid/ofab184.

[159] Lin CW, Yang HM, Hung SY, Chen IW, Huang YY. The analysis for time of referral to a medical center among patients with diabetic foot infection. BMC Fam Pract. 2021; 22: 16. https://doi.org/10.1186/s12875-020-01363-y.

[160] Chang BB, Darling RC, 3rd, Paty PS, Lloyd WE, Shah DM, Leather RP. Expeditious management of ischemic invasive foot infections. Cardiovasc Surg. 1996; 4: 792-5. https://doi.org/10.1177/096721099600400622.

[161] Elraiyah T, Domecq JP, Prutsky G, Tsapas A, Nabhan M, Frykberg RG, et al. A systematic review and meta-analysis of debridement methods for chronic diabetic foot ulcers. J Vasc Surg. 2016; 63: 37S-45S.e2. https://doi.org/10.1016/j.jvs.2015.10.002.

[162] Dayya D, O’Neill OJ, Huedo-Medina TB, Habib N, Moore J, Iyer K. Debridement of diabetic foot ulcers. Adv Wound Care (New Rochelle). 2022; 11: 666-86. https://doi.org/10.1089/wound.2021.0016.

[163] Lazaro-Martinez JL, Aragon-Sanchez J, Garcia-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial.Diabetes Care. 2014; 37: 789-95. https://doi.org/10.2337/dc13-1526.

[164] Gariani K, Pham TT, Kressmann B, Jornayvaz FR, Gastaldi G, Stafylakis D, et al. Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, noninferiority pilot trial. Clin Infect Dis. 2021; 73: e1539-45. https://doi.org/10.1093/cid/ciaa1758.

[165] Hutting KH, Aan de Stegge WB, van Netten JJ, Ten Cate WA, Smeets L, Welten G, et al. Surgical treatment of diabetic foot ulcers complicated by osteomyelitis with gentamicin-loaded calcium sulphate-hydroxyapatite biocomposite. J Clin Med. 2021; 10. https://doi.org/10.3390/jcm10020371.

[166] Ramanujam CL, Stuto AC, Zgonis T. Surgical treatment of midfoot Charcot neuroarthropathy with osteomyelitis in patients with diabetes: a systematic review. J Wound Care. 2020; 29: S19-28. https://doi.org/10.12968/jowc.2020.29.Sup6.S19.

[167] Dalla Paola L, Carone A, Morisi C, Cardillo S, Pattavina M. Conservative surgical treatment of infected ulceration of the first metatarsophalangeal joint with osteomyelitis in diabetic patients. J Foot Ankle Surg. 2015; 54: 536-40. https://doi.org/10.1053/j.jfas.2014.08.004.

[168] Widatalla AH, Mahadi SE, Shawer MA, Mahmoud SM, Abdel-mageed AE, Ahmed ME. Diabetic foot infections with osteomyelitis: efficacy of combined surgical and medical treatment. Diabet Foot Ankle. 2012; 3: 3. https://doi.org/10.3402/dfa.v3i0.18809.

[169] Tseng W, Bolla M, Wong A, Mendeszoon ER, Pham HT. Metatarsal osteotomy versus metatarsal head resection for distal diabetic foot ulcers. J Am Podiatr Med Assoc. 2024; 114. https://doi.org/10.7547/20-090.

[170] Sanz-Corbalan I, Lazaro-Martinez JL, Aragon-Sanchez J, Garcia-Morales E, Molines-Barroso R, Alvaro-Afonso FJ. Analysis of ulcer recurrences after metatarsal head resection in patients who underwent surgery to treat diabetic foot osteomyelitis. Int J Low Extrem Wounds. 2015; 14: 154-9. https://doi.org/10.1177/1534734615588226.

[171] Hachmoller A.Outcome of minor amputations at the diabetic foot in relation to bone histopathology: a clinical audit. Zentralbl Chir. 2007; 132: 491-6. https://doi.org/10.1055/s-2007-981371.

[172] Brown ML, Tang W, Patel A, Baumhauer JF. Partial foot amputation in patients with diabetic foot ulcers. Foot Ankle Int. 2012; 33: 707-16. https://doi.org/10.3113/FAI.2012.0707.

[173] Haller TV, Kaiser P, Kaiser D, Berli MC, Uckay I, Waibel FWA. Outcome of ray resection as definitive treatment in forefoot infection or ischemia: a cohort study. J Foot Ankle Surg. 2020; 59: 27-30. https://doi.org/10.1053/j.jfas.2019.06.003.

[174] Winkler E, Schoni M, Krahenbuhl N, Uckay I, Waibel FWA. Foot osteomyelitis location and rates of primary or secondary major amputations in patients with diabetes. Foot Ankle Int. 2022; 43: 957-67. https://doi.org/10.1177/10711007221088552.

[175] Stone PA, Back MR, Armstrong PA, Flaherty SK, Keeling WB, Johnson BL, et al. Midfoot amputations expand limb salvage rates for diabetic foot infections. Ann Vasc Surg. 2005; 19: 805-11. https://doi.org/10.1007/s10016-005-7973-3.

[176] Yammine K, El-Alam A, Assi C. Outcomes of partial and total calcanectomies for the treatment of diabetic heel ulcers complicated with osteomyelitis. A systematic review and meta-analysis. Foot Ankle Surg. 2021; 27: 598-605. https://doi.org/10.1016/j.fas.2020.07.014.

[177] Niazi NS, Drampalos E, Morrissey N, Jahangir N, Wee A, Pillai A. Adjuvant antibiotic loaded bio composite in the management of diabetic foot osteomyelitis-a multicentre study. Foot (Edinb). 2019; 39: 22-7. https://doi.org/10.1016/j.foot.2019.01.005.

[178] Pinzur MS, Noonan T. Ankle arthrodesis with a retrograde femoral nail for Charcot ankle arthropathy. Foot Ankle Int. 2005; 26: 545-9. https://doi.org/10.1177/107110070502600709.

[179] Ersin M, Demirel M, Chodza M, Bilgili F, Kilicoglu OI. Mid-term results of hindfoot arthrodesis with a retrograde intra-medullary nail in 24 patients with diabetic Charcot neuroarthropathy. Acta Orthop. 2020; 91: 336-40. https://doi.org/10.1080/17453674.2020.1746605.

[180] Chraim M, Krenn S, Alrabai HM, Trnka HJ, Bock P. Mid-term follow-up of patients with hindfoot arthrodesis with retrograde compression intramedullary nail in Charcot neuroarthropathy of the hindfoot. Bone Joint J. 2018; 100-B: 190-6. https://doi.org/10.1302/0301-620X.100B2.BJJ-2017-0374.R2.

[181] Pinzur MS. Neutral ring fixation for high-risk nonplantigrade Charcot midfoot deformity. Foot Ankle Int. 2007; 28: 961-6. https://doi.org/10.3113/FAI.2007.0961.

[182] Faglia E, Clerici G, Caminiti M, Curci V, Somalvico F. Influence of osteomyelitis location in the foot of diabetic patients with transtibial amputation. Foot Ankle Int. 2013; 34: 222-7. https://doi.org/10.1177/1071100712467436.

[183] Custer PL.Use of a scalp vein infusion set in oculo-plastic surgery. Ophthalmic Surg. 1989; 20: 68-9. https://doi.org/10.3928/1542-8877-19890101-17.

[184] Cook J, Cook E, Landsman AS, Basile P, Dinh T, Lyons T, et al. A retrospective assessment of partial calcanectomies and factors influencing postoperative course. J Foot Ankle Surg. 2007; 46: 248-55. https://doi.org/10.1053/j.jfas.2007.03.016.

[185] Coerper S, Beckert S, Kuper MA, Jekov M, Konigsrainer A. Fifty percent area reduction after 4 weeks of treatment is a reliable indicator for healing-analysis of a single-center cohort of 704 diabetic patients. J Diabetes Complicat. 2009; 23: 49-53. https://doi.org/10.1016/j.jdiacomp.2008.02.001.

[186] Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003; 26: 1879-82. https://doi.org/10.2337/diacare.26.6.1879.

[187] Bekeny JC, Alfawaz A, Day J, Naz I, Attinger CE, Fan KL, et al. Indirect endovascular revascularization via collaterals: a new classification to predict wound healing and limb salvage. Ann Vasc Surg. 2021; 73: 264-72. https://doi.org/10.1016/j.avsg.2020.11.031.

[188] Biancari F, Juvonen T. Angiosome-targeted lower limb revascularization for ischemic foot wounds: systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2014; 47: 517-22. https://doi.org/10.1016/j.ejvs.2013.12.010.

[189] Huang TY, Huang TS, Wang YC, Huang PF, Yu HC, Yeh CH. Direct revascularization with the Angiosome concept for lower limb ischemia: a systematic review and meta-analysis. Medicine (Baltimore). 2015; 94: e1427. https://doi.org/10.1097/MD.0000000000001427.

[190] Chae KJ, Shin JY. Is Angiosome-targeted angioplasty effective for limb salvage and wound healing in diabetic foot?: A meta-analysis. PLoS One. 2016; 11:e0159523. https://doi.org/10.1371/journal.pone.0159523.

[191] Bosanquet DC, Glasbey JC, Williams IM, Twine CP. Systematic review and meta-analysis of direct versus indirect angiosomal revascularisation of infrapopliteal arteries. Eur J Vasc Endovasc Surg. 2014; 48: 88-97. https://doi.org/10.1016/j.ejvs.2014.04.002.

[192] Stimpson AL, Dilaver N, Bosanquet DC, Ambler GK, Twine CP. Angiosome specific revascularisation: does the evidence support it? Eur J Vasc Endovasc Surg. 2019; 57: 311-7. https://doi.org/10.1016/j.ejvs.2018.07.027.

[193] Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt CA, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer. Diabetes Metab Res Rev. 2024; 40: e3686. https://doi.org/10.1002/dmrr.3686.

[194] Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005; 366: 1925-34. https://doi.org/10.1016/S0140-6736(05)67704-5.

[195] Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med. 2022; 387: 2305-16. https://doi.org/10.1056/NEJMoa2207899.

[196] Bradbury AW, Hall JA, Popplewell MA, Meecham L, Bate GR, Kelly L, et al. Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial. BMJ. 2025; 388: e080881. https://doi.org/10.1136/bmj-2024-080881.

[197] Branch of lower extremity artery disease in professional Committee of Vascular Surgery in National Committee of cardiovascular experts, vascular surgery Committee of China Medical Education Association.Chinese expert consensus on the diagnosis and treatment of femoral-popliteal artery occlusive disease. Chin Circ J. 2022; 37: 669-76. https://doi.org/10.3969/j.issn.1000-3614.2022.07.003.

[198] Moxey PW, Hofman D, Hinchliffe RJ, Jones K, Thompson MM, Holt PJ. Trends and outcomes after surgical lower limb revascularization in England. Br J Surg. 2011; 98: 1373-82. https://doi.org/10.1002/bjs.7547.

[199] Zhen Y, Ren H, Chen J, Chang Z, Wang C, Zheng J. Systematic review and meta-analysis of drug-coated balloon angioplasty for In-stent restenosis in femoropopliteal artery disease. J Vasc Interv Radiol. 2022; 33: 368-374.e6. https://doi.org/10.1016/j.jvir.2021.12.007.

[200] Nolan BW, De Martino RR, Stone DH, Schanzer A, Goodney PP, Walsh DW, et al. Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass. J Vasc Surg. 2011; 54: 730-5discussion 735-736. https://doi.org/10.1016/j.jvs.2011.03.236.

[201] Jia X, Zhuang B, Wang F, Gu Y, Zhang J, Lu X, et al. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of Infrapopliteal artery lesions (AcoArt II-BTK). J Endovasc Ther. 2021; 28: 215-21. https://doi.org/10.1177/1526602820969681.

[202] Shannon AH, Mehaffey JH, Cullen JM, Upchurch GR, Jr, Robinson WP, 3rd. A comparison of outcomes after lower extremity bypass and repeat endovascular intervention following failed previous endovascular intervention for critical limb ischemia. Angiology. 2019; 70: 501-5. https://doi.org/10.1177/0003319718809430.

[203] Desai U, Kharat A, Hess CN, Milentijevic D, Laliberte F, Zuckerman P, et al. Incidence of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. Ann Vasc Surg. 2021; 75: 217-26. https://doi.org/10.1016/j.avsg.2021.02.025.

[204] Dosluoglu HH, Lall P, Blochle R, Harris LM, Dryjski ML. Clinical presentation and outcome after failed infrainguinal endovascular and open revascularization in patients with chronic limb ischemia. J Vasc Surg. 2013; 58: 98-104.e1. https://doi.org/10.1016/j.jvs.2012.12.076.

[205] Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European stroke organization (ESO)the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39: 763-816. https://doi.org/10.1093/eurheartj/ehx095.

[206] Alhewy MA, Abdo EM, Ghazala EAE, Khamis AA, Gado H, Abd-Elgawad WAA, et al. Outcomes of alprostadil As an adjuvant therapy with indirect Angiosomal revascularization in patients with critical limb ischemia after failure of direct revascularization. Ann Vasc Surg. 2024; 103: 58-67. https://doi.org/10.1016/j.avsg.2023.12.078.

[207] Falanga V.Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen. 2000; 8: 347-52. https://doi.org/10.1111/j.1524-475X.2000.00347.x.

[208] Schultz GS, Sibbald RG, Falanga V, Ayello EA, Dowsett C, Harding K, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003; 11 Suppl 1: S1-28. https://doi.org/10.1046/j.1524-475x.11.s2.1.x.

[209] Ligresti C, Bo F. Wound bed preparation of difficult wounds: an evolution of the principles of TIME. Int Wound J. 2007; 4: 21-9. https://doi.org/10.1111/j.1742-481X.2006.00280.x.

[210] NICE guidelines on treatment of diabetic ulcers[J]. Nurs Times. 2015; 111: 4.

[211] Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American podiatric medical association and the Society for Vascular Medicine. J Vasc Surg. 2016; 63: 3S-21. https://doi.org/10.1016/j.jvs.2015.10.003.

[212] Game F, Jeffcoate W, Tarnow L, Jacobsen JL, Whitham DJ, Harrison EF, et al. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial[J]. Lancet Diabetes Endocrinol. 2018; 6: 870-78. https://doi.org/10.1016/S2213-8587(18)30240-7

[213] Nasr M, El-Nawasany MA, Ali HE, El Nagar AE, Elsharawy AF, Mirdad DSA, et al. Effectiveness of injected versus topically applied platelet-rich plasma in diabetic foot ulcers: A randomized controlled trial with clinical and histopathological assessment[J]. JPRAS Open. 2025; 46: 22-32. https://doi.org/10.1016/j.jpra.2025.08.008

[214] OuYang H, Tang Y, Yang F, Ren X, Yang J, Cao H, et al. Platelet-rich plasma for the treatment of diabetic foot ulcer: a systematic review [J]. Front Endocrinol (Lausanne). 2023; 14: 1256081. https://doi.org/10.3389/fendo.2023.1256081

[215] Huang C, Liu HZ, Liang JB, Zhao W, Wang YS, Ruan LF, et al. In vitro and clinical evaluation of platelet-rich plasma combined with angioplasty in diabetic foot treatment[J]. World J Diabetes. 2025; 16: 110631. https://doi.org/10.4239/wjd.v16.i10.110631

[216] Edmonds M, Lazaro-Martinez JL, Alfayate-Garcia JM, Martini J, Petit JM, Rayman G, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018; 6: 186-96.

[217] Lobmann R, Augustin M, Lawall H, Tigges W, Potempa C, Thiem H, et al. Cost-effectiveness of TLC-sucrose octasulfate versus control dressings in the treatment of diabetic foot ulcers. J Wound Care. 2019; 28: 808-16.

[218] Chen P, Vilorio NC, Dhatariya K, Jeffcoate W, Lobmann R, McIntosh C, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2024; 40: e3786. https://doi.org/10.1002/dmrr.3786.

[219] Gottrup F, Cullen BM, Karlsmark T, Bischoff-Mikkelsen M, Nisbet L, Gibson MC. Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment.Wound Repair Regen. 2013; 21: 216-25. https://doi.org/10.1111/wrr.12020.

[220] Jude EB, Apelqvist J, Spraul M, Martini J, Silver Dressing Study G. Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers.Diabet Med. 2007; 24: 280-8. https://doi.org/10.1111/j.1464-5491.2007.02079.x.

[221] Tsang KK, Kwong EW, To TS, Chung JW, Wong TK. A pilot randomized, controlled study of nanocrystalline silver, manuka honey, and conventional dressing in healing diabetic foot ulcer. Evid Based Complement Alternat Med. 2017; 2017: 5294890. https://doi.org/10.1155/2017/5294890.

[222] Belcaro G, Cesarone MR, Errichi BM, Ricci A, Dugall M, Pellegrini L, et al. Venous and diabetic ulcerations: management with topical multivalent silver oxide ointment[J]. Panminerva Med. 2010; 52: 37-42.

[223] Jensen JL, Seeley J, Gillin B. Diabetic foot ulcerations. A controlled, randomized comparison of two moist wound healing protocols: Carrasyn hydrogel wound dressing and wet-to-moist saline gauze. Adv Wound Care. 1998; 11: 1-4.

[224] Huang YY, Lin CW, Cheng NC, Cazzell SM, Chen HH, Huang KF, et al. Effect of a novel macrophage-regulating drug on wound healing in patients with diabetic foot ulcers: a randomized clinical trial. JAMA Netw Open. 2021; 4: e2122607. https://doi.org/10.1001/jamanetworkopen.2021.22607.

[225] Chang SC, Lin CW, Chen JC, Wu YH, Chen SG, Huang YY, et al. Effects of ON101 for hard-to-heal diabetic foot ulcers in a randomized phase III trial: a post hoc analysis. Adv Wound Care (New Rochelle). 2024; 14: 381-92. https://doi.org/10.1089/wound.2023.0167.

[226] Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. 2010; 33: 998-1003. https://doi.org/10.2337/dc09-1754.

[227] Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg. 2003; 25: 513-8. https://doi.org/10.1053/ejvs.2002.1911.

[228] Fedorko L, Bowen JM, Jones W, Oreopoulos G, Goeree R, Hopkins RB, et al. Hyperbaric oxygen therapy does not reduce indications for amputation in patients with diabetes with nonhealing ulcers of the lower limb: a prospective, double-blind, randomized controlled clinical trial. Diabetes Care. 2016; 39: 392-9. https://doi.org/10.2337/dc15-2001.

[229] Driver VR, Reyzelman A, Kawalec J, French M. A prospective, randomized, blinded, controlled trial comparing transdermal continuous oxygen delivery to moist wound therapy for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2017; 63: 12-28.

[230] Frykberg RG, Franks PJ, Edmonds M, Brantley JN, Teot L, Wild T, et al. A multinational, Multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen (TWO2) therapy in the treatment of chronic diabetic foot ulcers: the TWO2 study. Diabetes Care. 2020; 43: 616-24. https://doi.org/10.2337/dc19-0476.

[231] Sharma R, Sharma SK, Mudgal SK, Jelly P, Thakur K. Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. Sci Rep. 2021; 11: 2189. https://doi.org/10.1038/s41598-021-81886-1.

[232] Zhao S, Guo F, Zang Y, Hu R, Yu X, Zhang H, et al. The association of the perioperative neutrophil-to-lymphocyte ratio with wound healing in patients with Wagner grade 3 and 4 diabetic foot ulcers after tibial cortex transverse transport surgery: a prospective observational cohort study. Front Endocrinol (Lausanne). 2024; 15: 1420232. https://doi.org/10.3389/fendo.2024.1420232.

[233] Yu L, Zhang D, Yin Y, Li X, Bai C, Zhou Q, et al. Tibial cortex transverse transport surgery improves wound healing in patients with severe type 2 DFUs by activating a systemic immune response: a cross-sectional study. Int J Surg. 2025; 111: 257-72. https://doi.org/10.1097/JS9.0000000000001897.

[234] Ding Y, Yu D, Huang H, Peng X, Yang S, Lin Z, et al. Combining tibial cortex transverse transport (TTT) and endovascular therapy (EVT) for limb salvage in chronic limb-threatening ischemia. Orthop Surg. 2024; 16: 2132-9. https://doi.org/10.1111/os.14222.

[235] Chen H, Yao L, Zhou Y, Dai J. Evaluation of Antibiotic-Loaded Bone Cement in Treatment of Infected Diabetic Foot: Systematic Review and Meta-Analysis[J]. Diabetes Metab Res Rev. 2024; 40: e70002. https://doi.org/10.1002/dmrr.70002

[236] Mendame Ehya RE, Zhang H, Qi B, Yu A. Application and Clinical Effectiveness of Antibiotic-Loaded Bone Cement to Promote Soft Tissue Granulation in the Treatment of Neuropathic Diabetic Foot Ulcers Complicated by Osteomyelitis: A Randomized Controlled Trial[J]. J Diabetes Res. 2021; 2021: 9911072. https://doi.org/10.1155/2021/9911072

[237] Bus SA, Armstrong DG, Crews RT, Gooday C, Jarl G, Kirketerp-Moller K, et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024; 40: e3647. https://doi.org/10.1002/dmrr.3647.

[238] Swanson T, Ousey K, Haesler E, Bjarnsholt T, Carville K, Idensohn P, et al. IWII wound infection in clinical practice consensus document: 2022 update. J Wound Care. 2022; 31: S10-21. https://doi.org/10.12968/jowc.2022.31.Sup12.S10.

[239] Chinese Diabetes Society, Chinese Society of Infectious Diseases, Chinese Society for Tissue Repair and Regeneration.Chinese guideline on prevention and management of diabetic foot (2019 edition) (III). Chin J Diabetes Mellitus. 2019; 11: 238-47. https://doi.org/10.3760/cma.j.issn.1674-5809.2019.04.004.

[240] Zhao S, Hu X, Zhao Y, Zhang Y, Jin Y, Hua F, et al. Hydrogel-based therapies for diabetic foot ulcers: recent developments and clinical implications. Burns Trauma. 2025; 13: tkae084. https://doi.org/10.1093/burnst/tkae084.

[241] Hinman CD, Maibach H. Effect of air exposure and occlusion on experimental human skin wounds. Nature. 1963; 200: 377-8. https://doi.org/10.1038/200377a0.

[242] Ji S, Liu X, Huang J, Bao J, Chen Z, Han C, et al. Consensus on the application of negative pressure wound therapy of diabetic foot wounds. Burns Trauma. 2021; 9: tkab018. https://doi.org/10.1093/burnst/tkab018.

[243] Santema TB, Poyck PP, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2016; 2: CD011255. https://doi.org/10.1002/14651858.CD011255.pub2.

[244] Banerjee J, Lasiter A, Nherera L. Systematic review of cellular, acellular, and matrix-like products and indirect treatment comparison between cellular/acellular and amniotic/nonamniotic grafts in the Management of Diabetic Foot Ulcers. Adv Wound Care (New Rochelle). 2024; 13: 639-51. https://doi.org/10.1089/wound.2023.0075.

[245] Ramanujam CL, Stuto AC, Zgonis T.Use of local intrinsic muscle flaps for diabetic foot and ankle reconstruction: a systematic review. J Wound Care. 2018; 27: S22-8. https://doi.org/10.12968/jowc.2018.27.Sup9.S22.

[246] Fitzgerald O’Connor EJ, Vesely M, Holt PJ, Jones KG, Thompson MM, Hinchliffe RJ. A systematic review of free tissue transfer in the management of non-traumatic lower extremity wounds in patients with diabetes. Eur J Vasc Endovasc Surg. 2011; 41: 391-9. https://doi.org/10.1016/j.ejvs.2010.11.013.

[247] Bhat S, Chia B, Barry IP, Panayi AC, Orgill DP. Free tissue transfer in diabetic foot ulcers: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2023; 66: 670-7. https://doi.org/10.1016/j.ejvs.2023.07.031.

[248] Milton SH. Pedicled skin-flaps-the fallacy of the length: width ratio. Br J Surg. 1969; 56: 381.

[249] Hidalgo DA, Shaw WW. Anatomic basis of plantar flap design. Plast Reconstr Surg. 1986; 78: 627-36. https://doi.org/10.1097/00006534-198611000-00013.

[250] Hahn HM, Jeong KS, Park MC, Park DH, Lee IJ. Free-flap transfer for coverage of Transmetatarsal amputation stump to preserve residual foot length. Int J Low Extrem Wounds. 2017; 16: 60-5. https://doi.org/10.1177/1534734616689508.

[251] Lazzarini PA, Armstrong DG, Crews RT, Gooday C, Jarl G, Kirketerp-Moller K, et al. Effectiveness of offloading interventions for people with diabetes-related foot ulcers: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2024; 40: e3650. https://doi.org/10.1002/dmrr.3650.

[252] Li B, Lin A, Huang J, Xie J, Liu Q, Yang C, et al. Total contact casts versus removable offloading interventions for the treatment of diabetic foot ulcers: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023; 14: 1234761. https://doi.org/10.3389/fendo.2023.1234761.

[253] Gutekunst DJ, Hastings MK, Bohnert KL, Strube MJ, Sinacore DR. Removable cast walker boots yield greater forefoot offloading than total contact casts. Clin Biomech (Bristol). 2011; 26: 649-54. https://doi.org/10.1016/j.clinbiomech.2011.03.010.

[254] Begg L, McLaughlin P, Vicaretti M, Fletcher J, Burns J. Total contact cast wall load in patients with a plantar forefoot ulcer and diabetes. J Foot Ankle Res. 2016; 9: 2. https://doi.org/10.1186/s13047-015-0119-0.

[255] Guo Z, Yue C, Qian Q, He H, Mo Z. Factors associated with lower-extremity amputation in patients with diabetic foot ulcers in a Chinese tertiary care hospital. Int Wound J. 2019; 16: 1304-13. https://doi.org/10.1111/iwj.13190.

[256] Hong CC, Tan JH, Lim SH, Nather A. Multiple limb salvage attempts for diabetic foot infections: is it worth it? Bone Joint J. 2017; 99-B: 1502-7. https://doi.org/10.1302/0301-620X.99B11.BJJ-2016-0793.R2.

[257] Musuuza J, Sutherland BL, Kurter S, Balasubramanian P, Bartels CM, Brennan MB. A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers. J Vasc Surg. 2020; 71: 1433-1446.e3. https://doi.org/10.1016/j.jvs.2019.08.244.

[258] Yammine K, El Alam A, Alqaysi B, Assi C. The internal pedal amputation as a salvage procedure in diabetic and ischemic foot infection. A meta-analysis. Foot Ankle Surg. 2022; 28: 159-65. https://doi.org/10.1016/j.fas.2021.03.008.

[259] Huang H, Xin R, Li X, Zhang X, Chen Z, Zhu Q, et al. Physical therapy in diabetic foot ulcer: research progress and clinical application. Int Wound J. 2023; 20: 3417-34. https://doi.org/10.1111/iwj.14196.

[260] Heng L, Jingying Z. Effect of Roy adaptation mode combined with rehabilitation exercise nursing on postoperative diabetic foot amputation patients. Chin J Trauma Disabil Med. 2024; 32: 91-4. https://doi.org/10.13214/j.cnki.cjotadm.2024.008.024.

[261] Fard B, Persoon S, Jutte PC, Daemen JHC, Lamprou DA, Hoope WT, et al. Amputation and prosthetics of the lower extremity: the 2020 Dutch evidence-based multidisciplinary guideline. Prosthetics Orthot Int. 2023; 47: 69-80. https://doi.org/10.1097/PXR.0000000000000170.

[262] Zhao Q, Wu M, Zhou F, Chen B, Wang ZG, Ren SC, et al. Effects of graded health education on foot care behaviors among diabetic patients in communities. Chin J Prev Contr Chron Dis. 2022; 30: 426-30436. https://doi.org/10.16386/j.cjpccd.issn.1004-6194.2022.06.006.

[263] Hurley L, Kelly L, Garrow AP, Glynn LG, McIntosh C, Alvarez-Iglesias A, et al. A prospective study of risk factors for foot ulceration: the west of Ireland diabetes foot study. QJM. 2013; 106: 1103-10. https://doi.org/10.1093/qjmed/hct182.

[264] Peters EJ, Lavery LA. International working group on the diabetic F. Effectiveness of the diabetic foot risk classification system of the international working group on the diabetic foot. Diabetes Care. 2001; 24: 1442-7. https://doi.org/10.2337/diacare.24.8.1442.

[265] Reid KS, Martin BD, Duerksen F, Nicolle LE, Garrett M, Simonsen JN, et al. Diabetic foot complications in a northern Canadian aboriginal community. Foot Ankle Int. 2006; 27: 1065-73. https://doi.org/10.1177/107110070602701212.

[266] Amini MR, Sanjari M, Mohajeri Tehrani MR, Nasli E, Yazdanpanah L, Mousavi Z, et al. Evaluation of foot self-care status and foot screening problems in patients with diabetes in Iran: a national multicenter study. BMC Endocr Disord. 2023; 23: 178. https://doi.org/10.1186/s12902-023-01401-7.

[267] Viswanathan V, Gupta A, Devarajan A, Kumpatla S, Shukla S, Agarwal S, et al. Early screening for foot problems in people with diabetes is the need of the hour: ’save the feet and keep walking campaign’ in India. BMJ Open Diabetes Res Care. 2024; 12: 10.1136/bmjdrc-2024-004064. https://doi.org/10.1136/bmjdrc-2024-004064.

[268] Vatankhah N, Noudeh YJ, Khamseh ME, Baradaran HR. Screening people with type 2 diabetes at risk for foot ulceration in Iran. Diabetes Technol Ther. 2010; 12: 731-6. https://doi.org/10.1089/dia.2010.0035.

[269] Elsharawy MA, Hassan K, Alawad N, Kredees A, Almulhim A. Screening of diabetic foot in surgical inpatients: a hospital-based study in Saudi Arabia. Int J Angiol. 2012; 21: 213-6. https://doi.org/10.1055/s-0032-1330230.

[270] Drovandi A, Seng L, Golledge J. Effectiveness of educational interventions for diabetes-related foot disease: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2024; 40: e3746. https://doi.org/10.1002/dmrr.3746.

[271] Xiang Y, Luo P, Cai X, Tang Y, Wu Z. Results of a pilot study of patient-to-patient education strategy on self-management among glycemic uncontrolled patients with diabetes. Patient Prefer Adherence. 2017; 11: 787-93. https://doi.org/10.2147/PPA.S130060.

[272] Chen SM, Jo Wu CJ. Investigating the effects of digital foot self-management program on enhancing self-efficacy and self-care behavior among community-dwelling older adults with type 2 diabetes: a randomized controlled trial. Digit Health. 2023; 9: 20552076231220791. https://doi.org/10.1177/20552076231220791.

[273] Rahaman HS, Jyotsna VP, Sreenivas V, Krishnan A, Tandon N. Effectiveness of a patient education module on diabetic foot Care in Outpatient Setting: an open-label randomized controlled study. Indian J Endocrinol Metab. 2018; 22: 74-8. https://doi.org/10.4103/ijem.IJEM_148_17.

[274] Hadi Sulistyo AA, Sae Sia W, Maneewat K. The effect of a foot care camp on diabetic foot care knowledge and the behaviours of individuals with diabetes mellitus. J Res Nurs. 2018; 23: 416-25. https://doi.org/10.1177/1744987118765903.

[275] Nguyen TPL, Edwards H, Do TND, Finlayson K. Effectiveness of a theory-based foot care education program (3STEPFUN) in improving foot self-care behaviours and foot risk factors for ulceration in people with type 2 diabetes. Diabetes Res Clin Pract. 2019; 152: 29-38. https://doi.org/10.1016/j.diabres.2019.05.003.

[276] Obilor HN, Veryha O, Weisz T, Botros M, Wilson R, Tranmer J, et al. The feasibility of a social media-based foot self-management education and support program for adults with diabetes: a partially randomized preference trial. PEC Innov. 2024; 5: 100307. https://doi.org/10.1016/j.pecinn.2024.100307.

[277] Ronnemaa T, Hamalainen H, Toikka T, Liukkonen I. Evaluation of the impact of podiatrist care in the primary prevention of foot problems in diabetic subjects. Diabetes Care. 1997; 20: 1833-7. https://doi.org/10.2337/diacare.20.12.1833.

[278] Fu XJ, Hu SD, Peng YF, Zhou LY, Shu T, Song DD. Observation of the effect of one-to-one education on high-risk cases of diabetic foot. World J Clin Cases. 2021; 9: 3265-72. https://doi.org/10.12998/wjcc.v9.i14.3265.

[279] Dincer B, Bahcecik N. The effect of a mobile application on the foot care of individuals with type 2 diabetes: A randomised controlled study [J]. Health Education Journal. 2021; 80: 425-37. https://doi.org/10.1177/0017896920981617

[280] Bicer EK, Enc N. Evaluation of foot care and self-efficacy in patients with diabetes in Turkey: an interventional study. International journal of diabetes in developing countries. 2016; 36: 334-44. https://doi.org/10.1007/s13410-016-0464-y

[281] Bus SA, Sacco ICN, Monteiro-Soares M, Raspovic A, Paton J, Rasmussen A, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024; 40: e3651. https://doi.org/10.1002/dmrr.3651.

[282] Luo B, Cai Y, Chen D, Wang C, Huang H, Chen L, et al. Effects of special therapeutic footwear on the prevention of diabetic foot ulcers: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Res. 2022; 2022: 9742665. https://doi.org/10.1155/2022/9742665.

[283] Azuma H, Ikura K, Miura J, Babazono T. A fact-finding survey on pre-ulcerative lesions of foot in patients with diabetes: analysis using the diabetes study from the Center of Tokyo Women’s medical university 2018 (DIACET 2018). Diabetol Int. 2023; 14: 397-405. https://doi.org/10.1007/s13340-023-00649-7.

[284] Lucoveis MLS, Gamba M, Silva EQ, Pinto LAS, Sacco ICN. The effects of the use of customized silicone digital orthoses on pre-ulcerative lesions and plantar pressure during walking in people with diabetic neuropathy: a study protocol for a randomized controlled trial.Contemp Clin Trials Commun. 2024; 37: 101247. https://doi.org/10.1016/j.conctc.2023.101247.

[285] Shen Q, Li B, Chen H, Gao S, Hu Y, Sun Y, et al. Podiatrist intervention could reduce the incidence of foot ulcers in patients with diabetes: a hospital survey in China. J Wound Care. 2024; 33: S25-32. https://doi.org/10.12968/jowc.2024.33.Sup4.S25.

[286] Pataky Z, Golay A, Faravel L, Da Silva J, Makoundou V, Peter-Riesch B, et al. The impact of callosities on the magnitude and duration of plantar pressure in patients with diabetes mellitus. A callus may cause 18,600 kilograms of excess plantar pressure per day. Diabetes Metab. 2002; 28: 356-61.

[287] Pitei DL, Lord M, Foster A, Wilson S, Watkins PJ, Edmonds ME. Plantar pressures are elevated in the neuroischemic and the neuropathic diabetic foot. Diabetes Care. 1999; 22: 1966-70. https://doi.org/10.2337/diacare.22.12.1966.

[288] Scott JE, Hendry GJ, Locke J. Effectiveness of percutaneous flexor tenotomies for the management and prevention of recurrence of diabetic toe ulcers: a systematic review. J Foot Ankle Res. 2016; 9: 25. https://doi.org/10.1186/s13047-016-0159-0.

[289] van Netten JJ, Raspovic A, Lavery LA, Monteiro-Soares M, Rasmussen A, Sacco ICN, et al. Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36 Suppl 1: e3270. https://doi.org/10.1002/dmrr.3270.

[290] Bus SA, van Deursen RW, Armstrong DG, Lewis JE, Caravaggi CF, Cavanagh PR, et al. Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: a systematic review. Diabetes Metab Res Rev. 2016; 32 Suppl 1: 99-118. https://doi.org/10.1002/dmrr.2702.

[291] Asko Andersen J, Rasmussen A, Engberg S, Bencke J, Frimodt-Moller M, Kirketerp-Moller K, et al. Effect of flexor tendon tenotomy of the diabetic hammertoe on plantar pressure: a randomized controlled trial. BMJ Open Diabetes Res Care. 2024; 12: 10.1136/bmjdrc-2024-004398. https://doi.org/10.1136/bmjdrc-2024-004398.

[292] Yammine K, Mouawad J, Honeine MO, Assi C. Keller and interphalangeal joint resection arthroplasties for chronic noncomplicated diabetic ulcers of the hallux: a systematic review and meta-analysis. Foot Ankle Orthop. 2024; 9: 24730114241300139. https://doi.org/10.1177/24730114241300139.

[293] Shazadeh Safavi P, Jupiter DC, Panchbhavi V. A systematic review of current surgical interventions for Charcot neuroarthropathy of the midfoot. J Foot Ankle Surg. 2017; 56: 1249-52. https://doi.org/10.1053/j.jfas.2017.06.011.

[294] Meloni M, Giurato L, Monge L, Miranda C, Scatena A, Raggianti B, et al. Effect of a multidisciplinary team approach in patients with diabetic foot ulcers on major adverse limb events (MALEs): systematic review and meta-analysis for the development of the Italian guidelines for the treatment of diabetic foot syndrome. Acta Diabetol. 2024; 61: 543-53. https://doi.org/10.1007/s00592-024-02246-9.

[295] Meza-Torres B, Carinci F, Heiss C, Joy M, de Lusignan S. Health service organisation impact on lower extremity amputations in people with type 2 diabetes with foot ulcers: systematic review and meta-analysis. Acta Diabetol. 2021; 58: 735-47. https://doi.org/10.1007/s00592-020-01662-x.

[296] Somayaji R, Elliott JA, Persaud R, Lim M, Goodman L, Sibbald RG. The impact of team based interprofessional comprehensive assessments on the diagnosis and management of diabetic foot ulcers: a retrospective cohort study. PLoS One. 2017; 12:e0185251. https://doi.org/10.1371/journal.pone.0185251.

[297] Lo ZJ, Chandrasekar S, Yong E, Hong Q, Zhang L, Chong LRC, et al. Clinical and economic outcomes of a multidisciplinary team approach in a lower extremity amputation prevention programme for diabetic foot ulcer care in an Asian population: a case-control study. Int Wound J. 2022; 19: 765-73. https://doi.org/10.1111/iwj.13672.

[298] Feng WZ, Ding YF, Sun XJ, Xu LF, Hu Y, Wang AP. Thinking and strategy of graded diagnosis and treatment of diabetic foot in China. Chin J Diabetes Mellitus. 2024; 16: 34-8. https://doi.org/10.3760/cma.j.cn115791-20230918-00167.